

**Safety and efficacy of natalizumab in Belgian multiple sclerosis patients:
Subgroup analysis of the natalizumab observational program**

van Pesch V, Bartholomé E, Bissay V, Bouquiaux O, Bureau M, Caekebeke J, Debruyne J, Declercq I, Decoo D, Denayer P, De Smet E, D'Hooghe M, Dubois B, Dupuis M, Sankari SE, Geens K, Guillaume D, van Landegem W, Lysandropoulos A, de Noordhout AM, Medaer R, Melin A, Peeters K, Ba RP, Retif C, Seeldrayers P, Symons A, Urbain E, Vanderdonckt P, Van Ingelghem E, Vanopdenbosch L, Vanroose E, Van Wijmeersch B, Willekens B, Willems C, Sindic C.

Acta neurologica Belgica

2014; 114(3):167-178

ARTICLE IDENTIFIERS

DOI: 10.1007/s13760-014-0308-9

PMID: unavailable

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: 91648948

pISSN: 0300-9009

eISSN: 2240-2993

OCLC ID: 01460938

CONS ID: sn 79008441

US National Library of Medicine ID: 247035

This article was identified from a query of the SafetyLit database.